RhumbLine Advisers’s Parabilis Medicines Inc PBLS Stock Holding History

RhumbLine Advisers’s Portfolio PBLS Stock Details PBLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.46M	Buy	+45,108	New	+$1.57M	﹤0.01%	2062

Other funds holding PBLS

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Alphabet Inc Mountain View, California $88.3B AUM 46.07% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $180M AUM 18.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Mitsubishi UFJ Asset Management Tokyo, Japan $194B AUM 32.2% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Matisse Capital Portland, Oregon $256M AUM 15.28% 1-Year Est. Return

RhumbLine Advisers's PBLS Position: Q3 2026 in Review

RhumbLine Advisers opened a new position in Parabilis Medicines Inc (PBLS) in Q3 2026: 45,108 shares worth $1.46M. The stake represents ﹤0.01% of the portfolio and ranks #2062 among its holdings.

45 funds tracked by Wall St. Rank hold PBLS as of Q3 2026.

RhumbLine Advisers held 45,108 shares of Parabilis Medicines Inc worth $1.46M as of Q3 2026.
Parabilis Medicines Inc was a new RhumbLine Advisers position in Q3 2026.
Parabilis Medicines Inc made up ﹤0.01% of RhumbLine Advisers's portfolio in Q3 2026, its #2062 holding.
45 funds tracked by Wall St. Rank held Parabilis Medicines Inc as of Q3 2026.

Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.